|1.||Uwagawa, Tadashi: 14 articles (01/2016 - 05/2007)|
|2.||Yanaga, Katsuhiko: 13 articles (01/2016 - 08/2009)|
|3.||Fujiwara, Yuki: 11 articles (01/2016 - 10/2010)|
|4.||Furukawa, Kenei: 10 articles (01/2016 - 10/2010)|
|5.||Shiba, Hiroaki: 10 articles (01/2016 - 10/2010)|
|6.||Misawa, Takeyuki: 10 articles (02/2015 - 08/2009)|
|7.||Ohashi, Toya: 9 articles (01/2016 - 10/2010)|
|8.||Haruki, Koichiro: 8 articles (01/2016 - 07/2011)|
|9.||Iwase, Ryota: 6 articles (01/2016 - 11/2012)|
|10.||Ranieri, Girolamo: 4 articles (10/2015 - 01/2013)|
11/01/2011 - "Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?"
11/01/2011 - "Nafamostat mesilate prophylaxis (20 or 50 mg) is effective in preventing post-ERCP pancreatitis. "
02/01/1992 - "FUT-175 showed protective effects on the course of severe acute pancreatitis only when given prophylactically at the beginning of the pancreatitis induced by the CDE diet."
04/01/2009 - "Nafamostat mesylate prophylaxis is partially effective in preventing post-ERCP pancreatitis. "
05/01/2015 - "We aimed to evaluate the efficacy of nafamostat on the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
10/01/2010 - "The aim of this study is to evaluate the therapeutic efficacy of nafamostat mesilate against pancreatic cancer. "
07/01/2011 - "In conclusion, adenovirus vector-mediated TNF-α gene therapy combined with nafamostat mesilate was effective for pancreatic cancer in mice."
09/01/2011 - "In vivo, the efficacy of nafamostat mesilate treatment was assessed using peritoneal dissemination of pancreatic cancer in mice. "
09/01/2013 - "We previously reported that nafamostat mesylate inhibited NF-κB activation and induced apoptosis in pancreatic cancer. "
05/01/2011 - "We previously reported nafamostat mesilate (FUT175) inhibits NF-κB activation and promotes apoptosis in pancreatic cancer. "
01/01/2014 - "Hence, nafamostat mesilate may be used as an effective and safe anticoagulant, without increasing the risk of major bleeding complications, in patients prone to bleeding. "
11/01/1993 - "A prospective, randomized trial was performed to assess the efficacy of FUT-175 in the reduction of postoperative bleeding tendency. "
01/01/2014 - "Hence, we conducted a prospective, randomized controlled study investigating the effect of nafamostat mesilate on mortality, CRRT filter life span and adverse events in patients with bleeding tendency. "
01/01/2014 - "Nafamostat mesilate may be one of the risk factors for spontaneous retroperitoneal bleeding."
03/01/2013 - "Although nafamostat mesilate induced activated partial thromboplastin time prolongation in 11 circuits (5.4%), bleeding episodes were not increased. "
02/01/1997 - "The results indicate that inadequate tissue perfusion in shock stimulates blood coagulation and that nafamostat mesilate might be beneficial in decreasing excessive blood coagulation."
04/01/1991 - "Nafamostat Mesilate given as therapy significantly improved the hemodynamic parameters, and prevented the animals from developing shock. "
05/01/2003 - "Likewise, T/HS-induced intestinal villus injury was less in the nafamostat-treated shock rats (P < 0.05). "
04/01/1988 - "[Effect of FUT-175 on endotoxin-induced shock in the dog]."
01/01/1982 - "The minimal effective dose of FUT-175 in systemic Forssman shock in guinea pigs was 6.25 mg/kg i.p. "
04/01/2012 - "This study tested whether nafamostat mesilate is associated with perioperative ischemic stroke. "
11/01/2014 - "Nafamostat mesilate, administered in conjunction with low-dose heparinization, served as an effective anticoagulant for early surgery in patients with AIE complicated by stroke, and caused no further deterioration of the cerebral lesions."
04/01/2012 - "Of the 190 (21.8%) patients who received nafamostat mesilate, 1 (0.5%) suffered ischemic stroke compared with 10 (1.5%) in 680 patients without nafamostat mesilate (Fisher exact test; p = 0.47; regression analysis; odds ratio, 0.35; 95% confidence interval, 0.45-2.8; p = 0.32); 3 (1.6%) patients with nafamostat mesilate died postoperatively within 30 days compared with 11 (1.6%) without nafamostat mesilate (Fisher exact test; p > 0.99, regression analysis; odds ratio, 0.98; 95% confidence interval, 0.27-3.5; p = 0.97). "
04/01/2012 - "The authors retrospectively identified the patients who received nafamostat mesilate and who suffered symptomatic ischemic stroke within 30 postoperative days. "
11/01/2014 - "Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke."
|1.||Protease Inhibitors (Protease Inhibitor)
|2.||Serine Proteases (Serine Protease)
|3.||Complement System Proteins (Complement)
|10.||urinastatin (MR 20)
|2.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|4.||Extracorporeal Membrane Oxygenation (ECMO)